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Abstract: The alkyne-azide cycloaddition, popularly known as the “click” reaction, has 
been extensively exploited in molecule/macromolecule build-up, and has offered 
tremendous potential in the design of nanomaterials for applications in a diverse range of 
disciplines, including biology. Some advantageous characteristics of this coupling include 
high efficiency, and adaptability to the environment in which the desired covalent linking 
of the alkyne and azide terminated moieties needs to be carried out. The efficient delivery 
of active pharmaceutical agents to specific organelles, employing nanocarriers developed 
through the use of “click” chemistry, constitutes a continuing topical area of research. In 
this review, we highlight important contributions click chemistry has made in the design of 
macromolecule-based nanomaterials for therapeutic intervention in mitochondria and  
lipid droplets.  
Keywords: click chemistry; copper catalyzed alkyne-azide cycloaddition; drug delivery; 
lipid bodies; mitochondria  
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1. Introduction  
In 2001 Sharpless introduced the concept of “click chemistry”, one of the most versatile and 
modular approaches to couple two reactive partners in a facile, quick, selective, reliable and high yield 
reaction under mild conditions [1]. Since then click chemistry has become one of the most common and 
reliable methods to link molecules covalently, and it finds applications in a variety of disciplines including 
the chemistry of nanomaterials, chemical biology, drug delivery, and medicinal chemistry [2–7]. The 
inherent properties of click chemistry are also characteristic of “green chemistry” reactions. Although 
the 1,3-dipolar Hüisgen cycloaddition of azides with terminal alkynes was discovered in 1963, the 
copper catalyzed alkyne-azide cycloaddition (CuAAC) has become increasingly popular in the last 
decade. One of the reasons for this is that the traditional 1,3-dipolar Hüisgen cycloaddition takes place 
at high temperatures [8,9]. In addition, CuAAC reaction can be performed in a variety of solvents such 
as water, ethanol or tert-butyl alcohol, etc. [10]. Other advantages of CuAAC reaction include its 
efficiency under physiological conditions, and its chemo-selectivity, which allows labeling of 
functional biomolecules such as peptides, proteins, nucleic acids, polysaccharides, etc. [11]. It has been 
suggested that copper catalyst used in the reaction could have some adverse effects related to its 
toxicity [12]. Alternatives to the use of Cu catalysts in the click reaction, such as metal free 
cycloaddition reactions [13], and the use of other metals in promoting this reaction [14], have sparked 
increasing interest in the scientific community. This review aims to summarize the elegant use of 
alkyne-azide click chemistry in conjugation and designing products, especially intended for 
applications in biology. We specifically highlight the design of nanocarriers for the delivery of 
therapeutic agents to mitochondria and lipid droplets, cell organelles of considerable importance in 
preventing a variety of pathological disorders. 
2. Copper Catalyzed Alkyne-Azide Cycloaddition (CuAAC) 
The 1,3-dipolar cycloaddition of azides with alkynes was first discovered by Hüisgen in 1963. 
However, it did not attract much interest until it was demonstrated that this high temperature reaction 
could also be carried out under mild conditions using Cu(I) as the catalyst, and with tremendous  
regio-selectivity (Scheme 1). This was discovered simultaneously and independently by Meldal and his 
group in Denmark, and Fokin and Sharpless in USA [9,10,15,16]. The coordination of Cu(I) to alkynes 
in an aqueous solution forming a copper-acetylide intermediate is an exothermic reaction. The azide 
binds to this Cu (I)-acetylide intermediate forming a six membered Cu(III)-metallacycle [10]. 
Subsequently, the triazole ring formation is very rapid [17], and the cycloaddition product is 
chemically inert or stable towards redox reactions, has strong dipole moment, hydrogen bond 
accepting ability and aromatic character [18]. Experimental and computational studies have shown that 
Cu(I) coordinates to the alkynes through polynuclear Cu(I) intermediates [17,19–23]. Recently, a detailed 
mechanism has been elucidated by Fokin and his colleagues [24]. The advantages of this alkyne-azide 
coupling reaction include an almost quantitative conversion, the robust nature of the products, 
biomolecular ligation, in vivo tagging [25–28], and use in the synthesis of linear polymers [29,30]. 
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Scheme 1. Copper-catalyzed alkyne-azide cycloaddition. 
 
The CuAAC reaction has been successfully introduced in many different scientific areas,  
and its potential has been demonstrated in materials chemistry [31], dendrimer build-up [32],  
polymers [33,34], nanoparticle synthesis [35] and interlocked molecules [36,37]. In dendrimer 
chemistry, CuAAC was used not only for the convergent [38] and divergent build-up [39,40], but also 
for the dendrimer functionalization, and introduction of multiple functionalities into the 
macromolecular architecture [32,41–46]. For biomedical applications the use of Cu in the reaction and 
its retention post-synthesis, poses potential toxicity risks, and thus could limit the use of this method 
for products intended for biology [12]. Copper metal is added in catalytic amounts in the reaction, and 
is subsequently removed after reaction by adding chelating ligands such ethylenediaminetetraacetic 
acid (EDTA). However, considering the potential adverse effects, even at picomolar levels, Cu-free 
click strategies have been developed recently which reduce the risk of transition metal related toxicity 
issues [47–50]. Copper-free reactions described by Bertozzi and her colleagues as strain promoted 
alkyne-azide cycloaddition (SPAAC) date back to the work done by George Wittig, who described the 
exothermic cycloaddition of cyclooctyne with phenyl azide leading to triazoles [51]. These reactions 
showed immense potential in vivo [52,53], and have been extended to label peptides [54], DNA [55,56] 
and lipids [57], to cross-linked hydrogels [58], polymers [59,60] and photodegradable star polymers [61]. 
The other type of SPAAC reactions include cycloadditions between strong 1,3-dipoles with enhanced 
reactivity such as nitrile oxides, nitrile imines and nitrones with unsaturated hydrocarbons [62–64], 
applicable in DNA bioconjugation reactions [65–68]. The following sections provide several examples 
of click chemistry reactions employed in developing nanocarriers for targeted drug delivery to  
cellular organelles. 
3. Drug Delivery  
Tremendous effort has been devoted to the development of nanocarriers for the efficient delivery of 
therapeutic agents to the targeted site [69]. In this regard macromolecules have offered tremendous 
potential [70], but such nanodelivery systems have to meet stringent requirements if they are to be 
employed for drug delivery [71,72]. The macromolecule based nanocarriers used for this purpose 
should be non-cytotoxic, remain intact prior to reaching the target site, and enhance the effectiveness 
of the selected drug. Although, significant efforts have been made in assembling macromolecule based 
nanocarriers using a variety of synthetic methodologies, challenges still remain in introducing  
multiple functions into a single platform. Click chemistry has offered new ways of developing  
nanomaterials [60,73,74], particularly those with multiple functional groups and architecture [75]. 
These moieties can be introduced within the nanocarrier architecture with high precision. Such 
nanoarchitectures have been exploited as suitable carriers for therapeutic agents and fluorescent labels 
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to deliver them to specific cells, cellular organelle, to either prevent cell death [76] or visualize them 
with or without drug delivery. A number of strategies to target cells with drugs had been adopted earlier, 
and these include carbodiimide, thiol-maleimide and biotin-avidin coupling to biomolecules [77]. As 
already mentioned, recent progress in click chemistry has allowed coupling reactions to be carried out 
under mild conditions, and in an aqueous medium with negligible unwanted toxic bye-products [1]. 
Using copper free alkyne-azide coupling, one can link a variety of peptides, antibodies and drugs to 
biocompatible synthetic macromolecules that have been specifically targeted to the cells [78–80]. 
Considering the focus of this review article, the following sections provide a few examples of 
nanodelivery systems targeting cell organelles, specifically mitochondria and lipid bodies (LBs).  
3.1. Mitochondria  
Mitochondria, cellular power plants, play pivotal homeostatic role in cellular functions such as 
cellular signaling, growth and differentiation, cell cycle regulation, electron transport, calcium storage 
and cellular death [81,82]. Mitochondrial dysfunction is implicated in a variety of pathological 
disorders such as aging, ischemia-reperfusion, cardiac disorders, neurodegenerative and neuromuscular 
diseases, obesity, and genetic disorders [83–86]. One of the major causes of damage in these 
conditions is the generation of mitochondrial reactive oxygen species [87]. N-acetylcysteine, α-lipoic 
acid and coenzyme Q10 (CoQ10) are some of the antioxidant therapeutics that have shown promise in 
neurodegenerative diseases [88–90]. CoQ10 or ubiquinone is a naturally occurring lipid-soluble 
vitamin-like benzoquinone derivative with 10 monounsaturated trans-isoprenoid units in the side 
chain, and acts as a cofactor for mitochondrial complexes I–III for the generation of ATP [91,92]. It is 
found in the inner mitochondrial and cellular membranes, blood and in high and low-density 
lipoproteins [93]. Some of the main disadvantages of selective drugs are their hydrophobicity, stability, 
bioavailability, inability to cross the membrane barriers and selective accumulation in the multi-membrane 
barrier organelles located in the cytoplasm, such as mitochondria. Targeting mitochondria with a 
variety of bioactive molecules and drugs is one strategy to overcome some of these hurdles [83]. Many 
strategies had been reported earlier for the delivery to mitochondria such as use of lipophilic  
cations [94–96], protein-nucleic acid [97], peptide-nucleic acid [98–101], protein and RNA [102–104], 
and peptides [105,106]. The efficient and organelle specific delivery of therapeutics continues to be a 
topical area, and nanocarriers based approaches are emerging. Unlike cellular targeting, the 
prerequisite for mitochondrial targeting includes the use of drug modifications or encapsulation into 
nanocarriers such as dendrimers. This would help not only cross several membrane barriers, but also 
have high accumulation in these organelles. The other advantage of using the nanocarrier systems is 
their ability for site specific targeting with improved efficacy and reduced toxicity [89,107–109]. 
Recently, our group synthesized multifunctional nanocarriers based on miktoarm polymers of the 
type ABC [A = poly(ethylene glycol (PEG), B = polycaprolactone (PCL), and C = triphenyl-phosphonium 
bromide (TPPBr)], for targeting mitochondria and to deliver coenzyme Q10 (CoQ10) [110] (Figure 1). 
The delivery system was synthesized using a combination of click chemistry with ring-opening 
polymerization, and subsequently self-assembled into nanosized micelles loaded with CoQ10. The 
loaded micelles of size 25–60 nm with a capacity of more than 70 wt% for CoQ10 were stable in 
solution for 3 months. The high loading efficiency in these clicked polymers, unlike other carrier 
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systems for CoQ10 [111,112], resulted in low drug loss, and showed high efficacy as nanotherapeutics 
against oxidative stress-induced cell damage [110].  
Figure 1. Self-assembly of the ABC miktoarm star polymer, and loading of CoQ10 into 
the resulting micelles.  
 
Targeting mitochondria with peptides is another approach in which CuAAC was used to  
conjugate a cyclic tumor targeting peptide LyP-1 (CGNKRTRGC) to iron oxide nanoparticles with  
azido-functionalized PEGylated groups [113] (Figure 2). This peptide binds to a mitochondrial peptide 
p32 that is overexpressed in tumor cells, macrophages and endothelial cells. This clicked product 
showed blood stability for >5 h in vivo which allowed its accumulation in the tumor interstitium. These 
nanocarriers could be specifically targeted to the tumor sites, providing a platform for the treatment by 
magnetic hyperthermia. Such a treatment is based on generation of heat by magnetic nanoparticles 
exposed to the alternating magnetic fields [114].  
Figure 2. Superparamagnetic iron oxide nanoparticle labeled with fluorochrome 
(TAMRA) and LyP-1 cyclic peptide (Reprinted with permission, [87]). 
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Another interesting approach to target mitochondrial enzyme carbonic anhydrases (CA-VA and VB) 
has been recently proposed. This approach was suggested as a new platform for the development  
of anti-obesity treatment strategies [115,116]. Carbonic anhydrases are ubiquitously expressed 
metallo(zinc)enzymes, involved in the gluconeogenesis, lipogenesis, ureagenesis and tumorigenicity [117]. 
The mitochondrial CA isozymes are involved in maintaining the availability of HCO3− for the 
formation of pyruvate from citrate. The pyruvate thus formed is translocated to the cytoplasm and is 
involved in the de novo lipogenesis [117]. Different strategies have been proposed in the synthesis of 
CA inhibitors (CAI). Weight loss was observed during the treatment with zonisamide (ZNS) and 
topiramate (TPM), containing sulfonamide (–SO2NH2) and sulfamate–(-OSO2NH2) moieties (Figure 3). 
These moieties enable an interaction with the zinc binding sites thereby inhibiting the CA function [118]. 
Figure 3. Glycoconjugate and metallocene-based CA inhibitors. The groups in red indicate 
the CA recognition (Zinc binding motif), green show the sugar-triazole tail and blue the 
metallocene-triazole tail. 
  
ZNS and TPM structures prompted Supuran and colleagues to investigate and synthesize new CA 
inhibitors. Using ‘click chemistry’ approach, both the glycoconjugates and metallocene-based CA 
inhibitors were prepared where benzenesulfonamide moiety was linked to sugar or metallocene tail 
through 1,2,3-triazole group [119,120]. These compounds were effective as CA inhibitors. Additional 
10 small molecules of CAI were synthesized using CuAAC method of the azido-benzenesulfonamide 
fragment with different substituents of phenyl acetylenes [115]. CA catalyzed CO2 hydration assay 
was performed to compare the inhibition potency of ZNS, TPM, and all the 10 aryl triazole inhibitors. 
These triazole inhibitors were stronger inhibitors of mitochondrial CA isozymes VA and VB as 
compared to ZNS and TPM.  
Other strategies including incorporation of mitochondrion-targeting peptides have been used to 
deliver drugs to this organelle [121,122]. More recently an interesting new approach was taken by 
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Dhar’s group [123]. This study showed the versatility of biodegradable high density lipoprotein-
nanoparticles for detection of plaques by targeting the collapse of the mitochondrial membrane 
potential. The same study described a rationally designed mitochondria-targeted polymeric 
nanoparticle (NP) system and its optimization for efficient delivery of various mitochondria-acting 
therapeutics by blending a targeted poly(d,l-lactic-co-glycolic acid)-block (PLGA-b)-poly(ethylene 
glycol) (PEG)-triphenylphosphonium (TPP) polymer (PLGA-b-PEG-TPP) with either nontargeted 
PLGA-b-PEG-OH or PLGA-COOH. An optimized formulation was identified through in vitro screening 
of a library of charge- and size-varied NPs. A programmable NP platform for the diagnosis and targeted 
delivery of therapeutics for mitochondrial dysfunction-related diseases was also described [123]. The 
same group also showed how in situ light activation amplifies the host immune responses when NPs 
deliver the photosensitizer to the mitochondria, and opening up the possibility of using mitochondria-
targeted-NP treated, light activated, cancer cell supernatants as possible vaccines [124]. An overview of 
strategies to target organelles by exploiting different nanotechnological tools was recently reported [125]. 
3.2. Lipid bodies (LB) 
Lipid bodies (LBs) are cytoplasmic organelles which have been historically considered cellular 
storage sites. LBs are phylogenetically conserved and ubiquitous organelles with many cellular 
functions [126–129]. More recently, they have been recognized as dynamic, communicating with 
different organelles including mitochondria [130,131]. Different stressful conditions resulting in 
mitochondrial damage can lead to LB accumulation. The endoplasmic reticulum (ER) is a major 
intracellular compartment involved in neutral lipid synthesis and LB biogenesis. Our studies indicated 
that mitochondrial disruption in cells exposed to cytotoxic nanocrystals is accompanied by LB 
accumulation [132]. LB accumulation commonly results from inhibition of mitochondrial fatty acid  
β-oxidation [133].  
Accumulation of LBs in leukocytes and macrophages follows their stimulation with pro-inflammatory 
agents including bacterial endotoxins (e.g., lipopolysaccharide from Gram negative bacteria) is well 
recognized [132,134]. Due to their prominence in inflammatory leukocytes, LBs are considered to be 
structural markers of inflammation. Therefore, pharmacological modulation of LB biosynthesis and 
composition presents an attractive strategy to correct LB abnormalities in different pathologies.  
To specifically target LBs, Kakkar and Maysinger developed a macromolecule-based delivery 
system using click chemistry [135]. The goal was to deliver niacin (and eventually other lipid-modifying 
drugs) to LBs by means of dendrimer and miktoarm polymer-based nanocarriers, in order to inhibit the 
activity of LB-localized enzymes. The construct associated with LBs, but the activities of different 
lipid synthesizing enzymes were not determined. The data from analyses of enzymatic activities 
contributing to lipid processing in association with LBs would provide valuable information for the 
development of disease-modifying therapeutics. The delivery vehicles were constructed on building blocks 
with orthogonal functionalities which allow the introduction of multi-tasking units one at a time [136]. The 
dendrimer based nanocarrier (Figure 4) was synthesized by clicking a building block with an arm with 
protected acetylene and another with a long chain alcohol, on to 1,3,5-triethynylbenzene [105]. Niacin, 
(vitamin B3) was then covalently attached by linking through the long chain alcohol leading to the 
formation of an ester bond. Upon cleaving the latter bond by cellular esterases, niacin is released from 
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its nanocarrier. The acetylene unit on the delivery vehicle was then deprotected, and BODIPY-azide 
was covalently linked using CuACC. The detection of the polymers at the subcellular level was made 
possible by the linked lipophilic fluorescent, non-polar dye, Bodipy 493/503. In order to assess the 
efficacy of the niacin-conjugated carriers as a LB targeting drug delivery system, the colocalization of 
nanocarrier with LBs was assessed by confocal microscopy. The intracellular LBs were labeled with 
the fluorescent dye Bodipy 493/503 (green) which selectively labels neutral lipids, and the 
nanocarriers were labeled with red fluorescent dye. Within seconds, the carriers entered the cell’s 
cytosol and localized on cytoplasmic LBs, revealing yellow regions corresponding to the LBs (Figure 4). 
The achievement of specific targeting of niacin-macromolecules to LBs described by Maysinger and 
Kakkar [135] may open new means of drug delivery in pathologies characterized by abnormalities in 
lipid metabolism and lipid storage, such as metabolic steatosis, obesity and atherosclerosis. 
Figure 4. Dendrimer with covalently linked BODIPY dye, and confocal images A: Red 
BODIPY conjugated dendrimer; B: Lipid droplets labeled with Green BODIPY; and  
C: Overlay of A and B. 
  
We have also synthesized delivery vehicles using click reaction for linkage of α-lipoic acid (LA) 
and Bodipy [136] to target cellular lipid droplets. Lipoic acid, an essential cellular cofactor, 
antioxidant, chelating agent and transcription factor regulator [137], is easily taken up by cells and 
reduced to dihydrolipoic acid which is more effective than LA. LA was covalently linked to the 
dendrimer which improved its intracellular retention, and showed therapeutic effectiveness. We have 
recently designed and prepared dendrimers using a combination of CuAAC with Diels-Alder (DA) 
click reaction in which LA was linked to the periphery of the dendrimer [138]. [4+2] cycloaddition of 
a diene with a dienophile, popularly known as the Diels-Alder reaction is another highly advantageous 
reaction belonging to the “click chemistry” family [139]. This alternative strategy has provided an 
additional straightforward route to the construction of a variety of macromolecules or their 
functionalization at the periphery. One important aspect of this cycloaddition is its thermal 
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reversibility, commonly referred to as the retro Diels-Alder reaction [140]. We have taken advantage 
of this property and designed a thermosensitive dendrimer based nanodelivery system for Lipoic acid. 
The dendrimer was synthesized using two different bifunctional units having an azide with two furan 
rings (AzFu2) and flexible acetylene arms. LA was then clicked via DA reaction to the peripheral furan 
moieties on the dendrimer. The dendrimer was non cytotoxic and the drug was released from it via a 
retro-Diels-Alder reaction at 37–42 °C [138]. This study demonstrated that retro-Diels-Alder reaction 
on moieties covalently linked to macromolecules based nanocarriers, can be carried out at ambient 
temperatures. It offers a highly exciting platform in which dendrimer-drug conjugates can be assembled 
using this “click” strategy, and anti-inflammatory agents covalently bound by Diels-Alder click reaction 
can be released, in a controlled manner, under physiological and pathological range of temperatures. 
Another example of Diels-Alder “click” chemistry used for the delivery of drugs through peptides 
was reported by Braun’s group [141]. It involved the delivery of a cytotoxic drug temozolomide (TMZ) 
using cyclic-RGD-ligand as cargo to target αvβ3 integrin receptor for cancer. The cytotoxic drug TMZ 
was ligated to the cRGD-ligand using Diels Alder reaction with inversion electron demand [141]. For 
evaluating the cellular location of this click product, a fluorescent tag dansyl was ligated. The  
cRGD-TMZ-dansyl complex when treated to MCF-7 cancer cells effectively binds on to the cell 
membrane which expresses high levels of αvβ3 integrin. This study also reports that the above click 
product selectively kills cancer cells with high efficacy as compared to only the TMZ drug treatment. 
In this section we provide examples of click chemistry to generate nanostructures targeting selected 
cellular organelles. Methodological details on imaging organelles have been recently reviewed [142]. 
3.3. Click Chemistry for the Synthesis of Nanocarriers with Anti-Inflammatory Properties 
Nimodipine (NIM), an active calcium channel blocker, is a hydrophobic drug with poor aqueous 
solubility. It is used in the prevention and treatment of cerebral vasospasm and ischemia, both of which 
occur during the subarachnoid hemorrhage or cerebral bleeding [143]. Clinically, NIM has limited use 
because its oral administration leads to rapid clearance through liver, making its availability as low as 
10%. Because of low water solubility and a need for solubilizing mediator, its administration can cause 
local adverse effects [109]. Recently, we reported the synthesis of AB2 type miktoarm polymer  
(A = polycaprolactone (PCL); B = polyethylene glycol (PEG)) based nanocarrier using click chemistry 
(Figure 5), for improving water solubility and delivery of nimodipine (NIM) [109]. The polymer was 
constructed on a core containing two alkynyl moieties facilitating the click reaction for linking azide 
terminated PEG, and one alcohol group for ring-opening polymerization of caprolactone. The polymer 
(PEG7752 - PCL5800) assembles into micellar structures into which NIM was loaded with high 
efficiency (up to 78%), using a co-solvent evaporation method. It led to ~200 fold increase in the 
aqueous solubility of NIM. The micelles loaded with NIM reduced LPS-induced nitric oxide and  
pro-inflammatory cytokines (IL-1β and TNF-α) in microglial cells, through a slow release delivery 
mechanism from the polymers. Intriguingly, the polymers themselves (without drug loading) have 
shown protection of microglial cells from the LPS stress, indicating anti-inflammatory role of these 
polymers towards neuro-inflammation. 
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Figure 5. Structure of AB2 miktoarm star polymer. 
 
Recently, Choi and Maysinger showed monitoring of the effectiveness of nanotherapeutics in vivo 
in an animal model of ischemic brain injury [144]. Progression of neurodegeneration and regression of 
the ischemic lesion upon therapeutic interventions were determined in real-time using luminescent 
nanocrystals. Intranasal administration of anti-inflammatory nanotherapeutics (micelle-incorporated 
nimodipine or minocycline) was effective in preventing lesion progression as evidenced by the smaller 
lesion volumes and by significantly improved motor functions. 
It was proposed earlier that the 4th generation poly(amidoamine) (PAMAM) based dendrimers 
could themselves exert anti-inflammatory effects in the absence of any anti-inflammatory drugs [145]. 
These studies motivated us to investigate the anti-inflammatory role of our low generation dendrimers 
(DG0 and DG1) with surface terminal acetylene and hydroxyl groups. These the dendrimers 
synthesized using “click” chemistry showed inhibition of LPS-induced nitric oxide (NO) and 
prostaglandin E2 (PGE2) release in the microglial cells without affecting the cell viability and 
mitochondrial metabolic activity [6]. NO and PGE2 are synthesized by the action of iNOS and COX-2. 
We subsequently investigated if the dendrimers were directly interacting with these enzymes. 
Computer assisted molecular docking studies were performed to understand their interaction with the 
enzymes. The results suggest that the low generation dendrimers with terminal -OH functionalities 
directly interact with the iNOS and COX-2 enzymes active sites more favorably than their acetylene 
terminated functional groups. The anti-inflammatory effect is mainly mediated by the dendrimers in 
which electrostatic and lipophilic properties are complementary to the enzyme binding active sites. In 
contrast, higher generation dendrimers are too large to fit the same binding site within the pocket, 
suggesting that they interact mainly with the exposed functional groups at the enzyme surface, or exert 
their effects mainly by modulating other molecular targets.  
4. Conclusions 
High fidelity coupling of alkynes with azides catalyzed by copper has offered a useful platform in 
the tailoring and design of multifunctional nanocarriers, and in providing a detailed understanding of 
timely therapeutic interventions. Articulation of this reaction in a variety of different environments has 
been the key to implementing the build-up of synthetic architectures, in which participating 
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components with different biological functions are placed at desired locations. Click chemistry has 
been utilized in developing a variety of multifunctional nanocarriers based on dendrimers and 
miktoarm polymers. These macromolecules, with their advantageous combination of properties, can be 
directed towards specific cell organelles, including mitochondria and lipid droplets. Due to ease with 
which sequential “click” reactions can be performed in these macromolecules, this methodology can 
be extended to the design of novel nanocarriers with any desired combination of ingredients. It is 
expected that branched (miktoarm stars) and hyperbranched (dendrimers) architectures will continue to 
play a pivotal role in biological and medical research and click chemistry will be an essential 
component in implementing the design of multivalent and multifunctional nanocarriers. 
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